Aarti Drugs

The Indian pharmaceutical sector benefits from strong domestic demand and export opportunities. Companies with diversified product portfolios and robust manufacturing capabilities are well-positioned.

Bullish for Aarti Drugs based on strong fundamentals and positive outlook. Monitor quarterly results for confirmation.

For Indian markets, this story mainly matters for AARTIDRUGS and the pharma pocket. The current signal is bullish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: strong fundamentals, healthy dividend payout, expected good quarterly results, diverse product portfolio Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Established in 1984, part of USD 265 million Aarti Group.
• •Produces a diverse range of drugs (Vitamins, Anti-arthritis, Anti-fungal, Antibiotics, etc.).
• •Total eight plants at two locations (Tarapur, Sarigam).
• •Stock trading at 1.06 times its book value.
• •Company expected to give good quarter.